BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2019;50:848-57. [PMID: 31483522 DOI: 10.1111/apt.15484] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820971214. [PMID: 33240396 DOI: 10.1177/1756284820971214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Nassar IO, Cheesbrough J, Quraishi MN, Sharma N. Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102032] [Reference Citation Analysis]
4 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
5 Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P, Akanbi O, Tripathi N, Yarra P, Su L, Flomenhoft D, Stromberg A, Barrett TA. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Dig Dis Sci 2021;66:2051-8. [PMID: 32710192 DOI: 10.1007/s10620-020-06486-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Pugliese D, Privitera G, Pizzolante F, Gasbarrini A, Guidi L, Armuzzi A. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:280-90. [PMID: 31646853 DOI: 10.23736/S1121-421X.19.02625-4] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Aardoom MA, Jongsma MME, de Vries A, Wolthoorn J, de Ridder L, Escher JC. Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020;71:501-7. [PMID: 32639455 DOI: 10.1097/MPG.0000000000002833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sengupta NK, Azizov A, Halder S, Xenodemetropoulos T, Armstrong D, Tse F, Marshall JK, Narula N. Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scand J Gastroenterol 2020;55:800-5. [PMID: 32574083 DOI: 10.1080/00365521.2020.1780470] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?Curr Opin Pharmacol. 2020;55:17-30. [PMID: 33039940 DOI: 10.1016/j.coph.2020.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Dulai PS, Wong ECL, Reinisch W, Colombel JF, Marshall JK, Narula N. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflamm Bowel Dis 2021:izab310. [PMID: 34967397 DOI: 10.1093/ibd/izab310] [Reference Citation Analysis]
12 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
13 Shannahan SE, Papamichael K, Cheifetz AS. Evidence Supporting High-Dose Use of Biologics in Clinical Practice. Curr Treat Options Gastro 2020;18:408-22. [DOI: 10.1007/s11938-020-00302-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Shukla R, Ananthakrishnan A. Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. Clin Gastroenterol Hepatol 2021;19:1108-10. [PMID: 33556336 DOI: 10.1016/j.cgh.2021.01.002] [Reference Citation Analysis]
15 Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol 2021;116:1709-19. [PMID: 34587127 DOI: 10.14309/ajg.0000000000001263] [Reference Citation Analysis]
16 Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther 2020;51:553-64. [PMID: 31867766 DOI: 10.1111/apt.15609] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
17 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
18 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bourchany A, Gilletta De Saint-Joseph C, Breton A, Barreau F, Mas E. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Curr Opin Pharmacol 2020;54:51-8. [PMID: 32947075 DOI: 10.1016/j.coph.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]